Micro<scp>RNA</scp>s are differentially deregulated in mammary malignant phyllodes tumour

Tsang, Julia Y. S.; Ni, Yun‐Bi; Ng, Enders Ko; Shin, Vivian Y.; Mak, Ko-Fung; Go, Edna May L; Tawasil, John; Chan, Siu‐Ki; Ko, Chun-Wai; Kwong, Ava; Tse, Gary M.

doi:10.1111/his.12648

Cited by 9 publications

(4 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the host of biological markers studied in phyllodes tumours, many with an association with grade, their use in defining grade and potential clinical behaviour in specific cases remains limited.…”

Section: Grading Of Phyllodes Tumoursmentioning

confidence: 99%

Phyllodes tumours of the breast: a consensus review

Ács²,

et al. 2015

Self Cite

View full text Add to dashboard Cite

Phyllodes tumours constitute an uncommon but complex group of mammary fibroepithelial lesions. Accurate and reproducible grading of these tumours has long been challenging, owing to the need to assess multiple stratified histological parameters, which may be weighted differently by individual pathologists. Distinction of benign phyllodes tumours from cellular fibroadenomas is fraught with difficulty, due to overlapping microscopic features. Similarly, separation of the malignant phyllodes tumour from spindle cell metaplastic carcinoma and primary breast sarcoma can be problematic. Phyllodes tumours are treated by surgical excision. However, there is no consensus on the definition of an appropriate surgical margin to ensure completeness of excision and reduction of recurrence risk. Interpretive subjectivity, overlapping histological diagnostic criteria, suboptimal correlation between histological classification and clinical behaviour and the lack of robust molecular predictors of outcome make further investigation of the pathogenesis of these fascinating tumours a matter of active research. This review consolidates the current understanding of their pathobiology and clinical behaviour, and includes proposals for a rational approach to the classification and management of phyllodes tumours.

show abstract

Section: Grading Of Phyllodes Tumoursmentioning

confidence: 99%

Phyllodes tumours of the breast: a consensus review

Ács²,

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…The ratios of miR-15b-5p, miR-20a-5p, miR-19a-3p, miR-92a-3p and miR-16-5p to internal reference miR-146b-3p in serum are differentially expressed in patients who suffer from benign or malignant lung nodules and can be used to differentiate squamous cell lung cancer and benign lung diseases [ 27 ]. There are few studies on miRNAs associated with PT, and it has been reported that miR-21, miR-155 and miR-335 are over-expressed in malignant PT, which promotes the development of malignant PT [ 16 , 17 ]. Therefore, we suggest that miRNAs also have a role in differentiating FA from BPT.…”

Section: Discussionmentioning

confidence: 99%

“…Detection of single miRNA or miRNA expression profiles in serum or biopsy tissue can be available for the differential diagnosis of diseases. A few studies have reported that miRNAs can act as differential biomarker of benign and malignant PT [ 16 , 17 ], but there is no relevant report on miRNA expression in BPT and FA.…”

Section: Introductionmentioning

confidence: 99%

miR-140-3p is a potential differential biomarker in benign phyllodes tumors and fibroadenoma of the breast

Liu

Bai

et al. 2022

BMC Women's Health

View full text Add to dashboard Cite

Background Benign phyllodes tumor (BPT) and fibroadenoma (FA) have some difficulties in differential diagnosis. BPT is often misdiagnosed as FA during the first operation and is not diagnosed until postoperative recurrence and reoperation. The intent of this research was to find and validate microRNAs (miRNAs) with significant differential expression between BPT and FA as novel potential differential biomarkers. Methods Tissue specimens from three BPT patients and three FA patients were selected to detect the expression of miRNAs by miRNA-Seq technique. Primary cells were extracted and cultured from fresh BPT and FA tissues by tissue-block culture. The expression of differentially expressed miRNA (DEmiRNA) was further verified by quantitative real-time polymerase chain reaction (qRT-PCR) in twelve BPT and eleven FA patient specimens as well as primary cells. Data with a P value < 0.05 were considered statistically significant. Results The miRNA-Seq results showed totally six DEmiRNA were identified, consisting of two downregulated genes and four upregulated genes in BPT. Further validation by qRT-PCR manifest that miR-140-3p was downregulated by approximately 70% in BPT. Conclusion miR-140-3p could become potential differential biomarker for BPT and FA.

show abstract

“…9 In addition, miRNAs serve as oncogenes or tumor suppressors in multiple cancers such as BC, 10 colorectal cancer. 11 Recent studies have shown that miRNAs were effective biomarkers for BC diagnosis, pathological grading, and prognosis, miR-21 was related to metastasis, 12 histological grade, 13 and chemoresistance; 14,15 poor survival was associated with miR-126-5p, and miR-93-5p. 16,17 However, much still remains unknown about the mechanics and significance of miRNAs in many aspects of this disease.…”

mentioning

confidence: 99%

Identification of prognostic biomarkers for breast cancer based on miRNA and mRNA co‐expression network

Yao

Liu

Gao

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Purpose Breast cancer (BC) remains a serious health threat for women due to its high incidence and the trend of rejuvenation. Accumulating evidence has highlighted that microRNAs (miRNAs) and messenger RNAs (mRNAs) could play important roles in various biological processes involved in the pathogenesis of BC. The present study aimed to identify potential prognostic biomarkers associated with BC. Methods Here, original gene expression profiles of patients with BC was downloaded from The Cancer Genome Atlas (TCGA) database. TargetScan, miRDB, and miRTarBase databases were used to predict the target genes of prognostic‐related differentially expressed miRNAs (DEMs). Subsequently, functional enrichment analysis and topological analysis were performed on the overlaps of target genes and differentially expressed mRNAs (DEGs), and Kaplan‐Meier analysis was used to predict prognosis‐related target genes to identify prognostic biomarkers. Results A total of 218 DEMs and 2222 DEGs were extracted in which eight miRNAs were associated with prognosis, and 278 target DEGs were screened out incorporated into functional enrichment analysis and protein‐protein interaction network visualization studies. Additionally, five hub genes (CXCL12, IGF1, LEF1, MMP1, and RACGAP1) were observed as potential biomarkers for BC prognosis through survival analysis. Conclusion We performed a distinctive correlation analysis of miRNA‐mRNA in BC patients, and identified eight miRNAs and five hub genes may be effective biomarkers for the prognosis of BC patients.

show abstract

MicroRNAs are differentially deregulated in mammary malignant phyllodes tumour

Abstract: Differential expression of miRs in PT could be useful in diagnosis and grading of PT. Their deregulated expression, together with the altered downstream targets, implicated their active involvement in PT malignant transformation.

Cited by 9 publications

References 49 publications

Phyllodes tumours of the breast: a consensus review

Phyllodes tumours of the breast: a consensus review

miR-140-3p is a potential differential biomarker in benign phyllodes tumors and fibroadenoma of the breast

Identification of prognostic biomarkers for breast cancer based on miRNA and mRNA co‐expression network

Contact Info

Product

Resources

About